Image pharmaphorum Editor Views & Analysis Cleanrooms-on-demand: a more efficient future for pharma? The ‘as a service’ (AAS) model transformed the IT industry – making innovative technologies accessible to businesses without the high price point that would previously have been a barrier.< Views & Analysis Why should pharma invest in digital products for those livin... Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges. Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks. News Manny Montalvo video Load more results
Views & Analysis Cleanrooms-on-demand: a more efficient future for pharma? The ‘as a service’ (AAS) model transformed the IT industry – making innovative technologies accessible to businesses without the high price point that would previously have been a barrier.<
Views & Analysis Why should pharma invest in digital products for those livin... Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges.
Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
